AWM
EW icon

Aberdeen Wealth Management’s Edwards Lifesciences EW Stock Holding History

Aberdeen Wealth Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
+1,758
New +$147K 0.08% 146
2022
Q2 		– Sell
-1,758
Closed -$207K – 168
2022
Q1 		$207K Hold
1,758
– – 0.14% 142
2021
Q4 		$228K Buy
+1,758
New +$205K 0.15% 133

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Aberdeen Wealth Management's EW Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Edwards Lifesciences (EW) in Q2 2026: 1,758 shares worth $159K. The stake represents 0.08% of the portfolio and ranks #146 among its holdings. This is a return to the name: Aberdeen Wealth Management previously reported a position in EW as recently as Q1 2022.

Aberdeen Wealth Management first reported a position in EW in Q4 2021 and has held it in 3 quarters since. The position peaked at $228K in Q4 2021. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Aberdeen Wealth Management held 1,758 shares of Edwards Lifesciences worth $159K as of Q2 2026.
  • Edwards Lifesciences was a new Aberdeen Wealth Management position in Q2 2026.
  • Edwards Lifesciences made up 0.08% of Aberdeen Wealth Management's portfolio in Q2 2026, its #146 holding.
  • Aberdeen Wealth Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 3 quarters since.
  • Aberdeen Wealth Management's Edwards Lifesciences position peaked at $228K in Q4 2021.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.